The study evaluates the economic costs and benefits of improving tuberculosis control interventions in Thailand.
Provider costs are determined on the basis of marginal treatment costs for varying case numbers and estimates of the cost of required infrastructure changes.
Indirect costs are calculated as income lost due to morbidity and premature mortality.
An epidemiological model is used to calculate case numbers and mortality under current control conditions and a scenario of improved control.
An improved control strategy initially leads to a higher number of detected cases.
For longer projection periods, the epidemiological impact of curing a higher proportion of infectious sources results in lower case numbers than those expected without programme improvement.
Model simulations show a reduction of total annual case numbers through improved control measures by an average 45% after a simulation period of 20 years.
The corresponding societal savings in form of reduced indirect costs from the disease are U.S. $2.4 billion.
Reductions in direct provider costs can be expected as a result of decreased numbers of detected cases for longer evaluation periods, as well as a lower proportion of multi-drug-resistant cases.
The mean value of predicted savings is U.S. $8.3 million.
Since this value is likely to be higher than the required investment in improved infrastructure, net savings can be expected. (...)
Mots-clés Pascal : Tuberculose, Mycobactériose, Bactériose, Infection, Analyse avantage coût, Economie santé, Programme sanitaire, Traitement, Prévention, Chimiothérapie, Homme, Thaïlande, Asie, Modèle, Epidémiologie
Mots-clés Pascal anglais : Tuberculosis, Mycobacterial infection, Bacteriosis, Infection, Cost benefit analysis, Health economy, Sanitary program, Treatment, Prevention, Chemotherapy, Human, Thailand, Asia, Models, Epidemiology
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 98-0008075
Code Inist : 002B05B02E. Création : 17/04/1998.